Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Credo Technology Group Holding Ltd (CRDO) vs Invesco Ltd. (IVZ) Price & Performance

Credo Technology Group Holding LtdTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Credo Technology Group Holding Ltd vs Invesco Ltd. — how do they compare? Credo Technology Group Holding Ltd trades at $216.55 (market cap $39.82B), while Invesco Ltd. trades at $29.51 (market cap $13.28B). The key difference: Credo Technology Group Holding Ltd is far larger — about 3× Invesco Ltd.'s market cap, and Invesco Ltd. pays a 2.86% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Invesco Ltd. for 77 Days on average.

CRDOIVZ
Market Cap
$39.82B$13.28B
Volume
9,451,5583,698,033
Sector
TechnologyFinancials
52-Week High
$302.52$33.31
52-Week Low
$87.81$22.44
Typical Hold Time
22 Days77 Days
Enterprise Value
$39.08B$23.45B
Dividend Yield
—2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Credo Technology Group Holding Ltd

CRDO trades at $211.86, down 3.7% on the day but maintains strong technical momentum with bullish moving averages and key support at $204. The company demonstrates exceptional growth with 114.7% YoY revenue expansion and 33.83% net margins, though valuation multiples remain elevated at P/E of 74.6. Recent earnings beats and analyst consensus of $267.33 price target suggest continued upside potential despite insider selling activity.

Outlook remains positive driven by AI infrastructure demand and optical technology expansion, with management targeting 85%+ revenue growth. Key risks include premium valuation, customer concentration, and execution challenges as the company scales. The stock offers growth exposure to high-speed connectivity solutions but requires monitoring of margin trends and competitive dynamics.

Invesco Ltd.

IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, though recent earnings beats in Q4 2025 and Q2 2026 show some operational resilience. Analyst consensus is mixed with a $33.14 price target, and the firm continues expanding its ETF suite, including the recent launch of the Invesco Nasdaq International Innovators 100 ETF.

The outlook remains cautious due to negative profitability margins and bearish technicals, but the absence of sell ratings and a dividend payment provide some support. Key risks include sustained negative net income and competitive pressures in the asset management sector, while potential upside hinges on improved earnings and AUM growth momentum.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRDO
50% Buy50% Sell
Avg holding period · 22 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About Credo Technology Group Holding Ltd

Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.

Read more on CRDO →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →